

## COUNTRY GENERAL INFORMATION (WHO, 2015)

Total population:	1,400,000,000
Gender F / M (%):	48.2 / 51.8
Population, age group <15/≥15 years (%):	18 / 82
Life expectancy at birth (F/M, years) (2015):	78 / 75
GDP (PPP int \$):	11,850
Income status:	Upper middle
Number of 1 <sup>st</sup> sub-national administrative level divisions, name:	34, Province

## EPIDEMIOLOGY

	VL	CL	PKDL	MCL
Endemicity status:	Endemic	Endemic	Non endemic	Non endemic
Number of new cases (incidence):	498	0	N/A	N/A
Number of relapses <sup>1</sup> :	No data	No data	N/A	N/A
<b>Total number of cases:</b>	<b>498</b>	<b>10</b>	<b>N/A</b>	<b>N/A</b>
Imported cases (#, %):	0, 0%	10, 100%	N/A	N/A
Gender distribution (% F):	42%	0%	N/A	N/A
Age group distribution (% < 5/5-14/>14):	86/3/11	0/0/100	N/A	N/A
Incidence rate (cases/10,000 population in endemic areas):	0.01	No data	N/A	N/A
Number of endemic 1 <sup>st</sup> sub-national administrative level divisions:	7	No data	N/A	N/A
Population at risk <sup>2</sup> (% # at risk/total population):	16% (229,718,479/1,400,000,000)	No data	N/A	N/A
Was there any outbreak?	Yes	No	N/A	N/A
Number of new <sup>3</sup> foci:	0	0	N/A	N/A


N/A = Not applicable; <sup>1</sup> Relapse in this country is defined as: "Any reappearance of VL symptoms within a period of 6 months after the end of treatment"; <sup>2</sup> Defined as "Number of people living in 1<sup>st</sup> sub-national administrative level endemic areas"; <sup>3</sup> Defined as "In this reporting period, an area at the 1<sup>st</sup> sub-national administrative level reporting cases for the first time ever".

## Monthly distribution of new cases (January-December)


2015	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	28	24	21	10	8	9	18	23	59	111	122	65
CL	1	0	0	1	1	0	2	0	2	0	1	2

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis

### Visceral leishmaniasis




### Cutaneous leishmaniasis




## Incidence rate/10,000 (at the national level) and number of new cases from 1998 to 2015

### Visceral leishmaniasis



### Cutaneous leishmaniasis



## Disease distribution of new VL and CL cases at province level per 10,000 population (2015)

### Visceral leishmaniasis



[www.who.int/leishmaniasis/Map-VL-China-2015.png](http://www.who.int/leishmaniasis/Map-VL-China-2015.png)

The boundaries and names shown and the designations used on these maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Map production: WHO/HIM/NTD/IDM

### Cutaneous leishmaniasis

CL data is unspecified

## CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	1950s
Type of surveillance:	Other
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	Deltamethrin and lambda-cyhalothrin
Year latest national guidelines:	2006
Is leishmaniasis notifiable (mandatory report)?	Yes
Is there a reservoir host control programme?	No
Number of leishmaniasis health facilities:	No data

## DIAGNOSIS

	VL	CL	PKDL	MCL
Number of people screened actively for:	No data	No data	N/A	No data
Number of people screened passively for:	No data	10	N/A	No data
Cases diagnosed by RDT* (% , # RDT+/ total VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT* (% , # RDT+/total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam* (parasitology) (% , # slides + / total cases):	No data	N/A	N/A	N/A
Proportion of positive slides (% , # slides + / total slides):	No data	N/A	N/A	N/A
Cases diagnosed clinically (% , # clinical cases/ total cases):	No data	No data	N/A	N/A
Proportion of CL cases with lesions equal to or greater than 4 cm*:	N/A	No data	N/A	N/A
Proportion of CL cases with 4 or more lesions* (% , # CL cases/ total CL cases):	N/A	No data	N/A	N/A
Percentage of cases with HIV coinfection:	No data	N/A	N/A	N/A

N/A = Not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

## TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? **Yes**
- ▶ Antileishmanial medicines included in the National Medicine List: **Sodium stibogluconate**

### TREATMENT OUTCOME

	VL	CL
Proportion of cases treated* (% , # treated cases/ total cases):	100% (498/498)	No data
Initial cure rate(% , # cases initially cured /total cases):	No data	No data
Failure rate <sup>4</sup> (% , # patients with treatment failure /total cases):	No data	No data
Case fatality rate (% , # patients who died/ total cases):	No data	No data

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL= post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis

\*These indicators only apply for new cases

<sup>4</sup> Failure in this country is defined as: "Signs and symptoms of VL persist or recur after the end of treatment"